Inventor · disambiguated record
Valentin Gribkoff
Also filed as: GRIBKOFF VALENTIN · GRIBKOFF VALENTIN K · GRIBKOFF VALENTIN KALA
17 granted patents·16 pending applications·392 citations·filing 1995–2023
95Inventor score
Files withBRISTOL MYERS SQUIBB CO12KNOPP NEUROSCIENCES INC6BOZIK MICHAEL E3GRIBKOFF VALENTIN2KNOPP BIOSCIENCES LLC2
Top patents by PatentIndex Score
33 records- 0193US8518926B2Compositions and methods of using (R)-pramipexoleBOZIK MICHAEL E·Filed 2007·Granted Aug 27, 2013·13 cites·31 claims
- 0292US8524695B2Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the sameBOZIK MICHAEL E·Filed 2008·Granted Sep 3, 2013·11 cites·11 claims
- 0392US6469042B1Fluoro oxindole derivatives as modulators if KCNQ potassium channelsBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Oct 22, 2002·32 cites·12 claims
- 0491US6271249B1Diphenyl imidazoles as potassium channel modulatorsBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Aug 7, 2001·38 cites·8 claims
- 0590US8017598B2Compositions of R(+) and S(−) pramipexole and methods of using the sameKNOPP NEUROSCIENCES INC·Filed 2007·Granted Sep 13, 2011·21 cites·42 claims
- 0689US5602169A3-substituted oxindole derivatives as potassium channel modulatorsBRISTOL MYERS SQUIBB CO·Filed 1996·Granted Feb 11, 1997·66 cites·10 claims
- 0789US5565483A3-substituted oxindole derivatives as potassium channel modulatorsBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Oct 15, 1996·75 cites·31 claims
- 0888US8445474B2Compositions of R(+) and S(−) pramipexole and methods of using the sameBOZIK MICHAEL E·Filed 2011·Granted May 21, 2013·11 cites·57 claims
- 0988US5869509ADiphenyl oxadiazolones as potassium channel modulatorsBRISTOL MYERS SQUIBB CO·Filed 1997·Granted Feb 9, 1999·63 cites·14 claims
- 1083US9849116B2Compositions and methods of using (R)-pramipexoleKNOPP BIOSCIENCES LLC·Filed 2015·Granted Dec 26, 2017·3 cites·14 claims
- 1176US6077861ADiphenyl triazoles as potassium channel modulatorsBRISTOL MYERS SQUIBB CO·Filed 1998·Granted Jun 20, 2000·30 cites·12 claims
- 1274US7041496B2DNA encoding rodent KCNQ2 potassium channelBRISTOL MYERS SQUIBB·Filed 2002·Granted May 9, 2006·2 cites·5 claims
- 1371US6939968B2Atropisomers of 3-substituted-4-arylquinolin-2-one derivativesBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Sep 6, 2005·6 cites·20 claims
- 1469US6893858B2Human kcnq5 potassium channel, methods and compositions thereofBRISTOL MYERS SQUIBB CO·Filed 2001·Granted May 17, 2005·4 cites·4 claims
- 1568US2024254186A1GLP-1 Receptor Agonists Having Improved Pharmacological and Drug Delivery PropertiesDARBIX LLC·Filed 2023·Application pending·0 cites
- 1664US2020155516A1Compositions and methods of using (r)-pramipexoleKNOPP BIOSCIENCES LLC·Filed 2020·Application pending·0 cites
- 1762US2011190356A1Compositions and Methods of Using (R)- PramipexoleKNOPP NEUROSCIENCES INC·Filed 2009·Application pending·0 cites
- 1861US2023015478A1Glp-1 receptor agonists having improved pharmacological and drug delivery propertiesRESOLUTE BIO INC·Filed 2022·Application pending·0 cites
- 1961US2013310430A1Compositions and methods of using (r)-pramipexoleKNOPP NEUROSCIENCES INC·Filed 2013·Application pending·0 cites
- 2058US2024295545A1Glioma therapyIMPERIAL COLLEGE INNOVATIONS LTD·Filed 2022·Application pending·0 cites
- 2157US2014031401A1Modified Release Formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and Methods of Using the SameKNOPP NEUROSCIENCES INC·Filed 2013·Application pending·0 cites
- 2255US6326526B1Melatonin receptor-deficient mice and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Dec 4, 2001·1 cites·11 claims
- 2355US5621007AMethod for regulation of transmembrane chloride conductanceBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Apr 15, 1997·16 cites·4 claims
- 2454US2009005304A1Human KCNQ5 potassium channel, methods and compositions thereofBRISTOL MYERS SQUIBB CO·Filed 2007·Application pending·0 cites
- 2552US2013230569A1Compositions of r(+) and s(-) pramipexole and methods of using the sameKNOPP NEUROSCIENCES INC·Filed 2013·Application pending·0 cites
- 2651US2005043293A1Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereofFiled 2004·Application pending·0 cites
- 2750US2005064491A1Human KCNQ5 potassium channel, methods and compositions thereofFiled 2004·Application pending·0 cites
- 2847US2013245081A1Compositions and Methods for Treating Amyotrophic Lateral SclerosisKNOPP NEUROSCIENCES INC·Filed 2012·Application pending·0 cites
- 2945US2013273557A1Compounds and methods of modulating mitochondrial bioenergetic efficiency through an interaction with atp synthase (complex v) and its subunitsGRIBKOFF VALENTIN·Filed 2011·Application pending·0 cites
- 3044US2002045566A1Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereofFiled 2001·Application pending·0 cites
- 3144US2011009460A1Compositions and methods for treating amyotrophic lateral sclerosisGRIBKOFF VALENTIN·Filed 2010·Application pending·0 cites
- 3242US6855829B23-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related diseaseBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Feb 15, 2005·0 cites·8 claims
- 3340US2002183335A12, 4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulatorsFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Valentin Gribkoff files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →